News

Public · Published

Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Acrivon Therapeutics announced that it will present research at the EORTC-NCI-AACR cancer symposium in Barcelona, November 18–20, 2026. The program includes a late-breaking oral presentation on safety, dose optimization, and preliminary antitumor activity in a Phase 1 study of ACR-2316, plus poster presentations.

Published:

Updated:

What happened

Acrivon Therapeutics announced that it will present research at the EORTC-NCI-AACR cancer symposium in Barcelona, November 18–20, 2026. The program includes a late-breaking oral presentation on safety, dose optimization, and preliminary antitumor activity in a Phase 1 study of ACR-2316, plus poster presentations.

Confirmed

Global impact / market context

The presentations may give investors more information about ACR-2316, an experimental drug, including early safety and activity findings. If later evidence supports further development, that could shape Acrivon’s research spending and prospects for future revenue; the article provides no results or commercial outlook yet.

Analyst inference

This is a planned scientific disclosure, not a report of a treatment approval or established patient benefit. The Phase 1 study is an early human-testing stage, so preliminary findings may inform later research but do not establish whether ACR-2316 works or can be sold.

Analyst inference

What to watch

  1. Watch for the November 20 oral presentation’s reported safety, dose optimization, and preliminary antitumor activity findings from the Phase 1 ACR-2316 study. Confirmed
  2. The company says copies of the presentations will be available on its website after the symposium presentations; check whether those materials add study details. Confirmed
  3. Any favorable early findings could support continued development, while safety concerns or limited activity could require changes in research plans and spending. Analyst inference

Evidence